DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

While we've known that a healthy diet reduces the overall chance of getting cancer, there's now evidence that one eating plan ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...

Panelists discuss how ciltacabtagene autoleucel (cilta-cel) demonstrates superior outcomes compared to real-world physician’s ...

Groundbreaking research at the Yale Cancer Center offered hope for patients diagnosed with Multiple Myeloma, a type of blood ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...